This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crowell, J. A. Articles by Fay, J. R. Search for Related Content PubMed PubMed Citation Articles by Crowell, J. A. Articles by Fay, J. R. Related Collections Epidemiology and Prevention Epidemiology and Prevention: Chemoprevention Cellular Pathobiology: Proliferation, Senescence, and Death Review Preclinical Intervention Preclinical Intervention: In Vitro: Drugs, Mechanisms Preclinical Intervention: In Vivo (Animals): Drugs, Nutritional Interventions, Mechanisms

Review

Targeting the AKT protein kinase for cancer chemoprevention

¹ Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland and ² CCS Associates, Mountain View, California

Requests for reprints: James A. Crowell, Division of Cancer Prevention, National Cancer Institute, NIH, Executive Plaza North, Room 2117, 900 Rockville Pike, Bethesda, MD 20892. Phone: 301-594-0459; Fax: 301-402-0553. E-mail: jc94h{at}nih.gov

The AKT protein kinase transduces signals from growth factors and oncogenes to downstream targets that control crucial elements in tumor development. The AKT pathway is one of the most frequently hyperactivated signaling pathways in human cancers. Available data are reviewed herein to support targeting the AKT kinase for cancer prevention. This review will present data to show that AKT is up-regulated in preneoplastic lesions across a broad range of target tissues, briefly describe drug development efforts in this area, and present evidence that down-regulation of AKT signaling may be a viable strategy to prevent cancer. [Mol Cancer Ther 2007;6(8):2139–48]

³ L. Kopelovich et al. The mTOR pathway as a potential target for cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2007;16:330–40.

Received 2/22/07; revised 5/30/07; accepted 6/29/07.

This article has been cited by other articles:

				P. Kaur, S. Shukla, and S. Gupta Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study Carcinogenesis, November 1, 2008; 29(11): 2210 - 2217. [Abstract] [Full Text] [PDF]

				D. Wang, M. S. Veena, K. Stevenson, C. Tang, B. Ho, J. D. Suh, V. M. Duarte, K. F. Faull, K. Mehta, E. S. Srivatsan, et al. Liposome-Encapsulated Curcumin Suppresses Growth of Head and Neck Squamous Cell Carcinoma In vitro and in Xenografts through the Inhibition of Nuclear Factor {kappa}B by an AKT-Independent Pathway Clin. Cancer Res., October 1, 2008; 14(19): 6228 - 6236. [Abstract] [Full Text] [PDF]

				Y. Yamada, A. Sanchez-Aguilera, E. B. Brandt, M. McBride, N. J. H. Al-Moamen, F. D. Finkelman, D. A. Williams, J. A. Cancelas, and M. E. Rothenberg FIP1L1/PDGFR{alpha} synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome Blood, September 15, 2008; 112(6): 2500 - 2507. [Abstract] [Full Text] [PDF]

				F. Kassie, I. Matise, M. Negia, D. Lahti, Y. Pan, R. Scherber, P. Upadhyaya, and S. S. Hecht Combinations of N-Acetyl-S-(N-2-Phenethylthiocarbamoyl)-L-Cysteine and myo-Inositol Inhibit Tobacco Carcinogen-Induced Lung Adenocarcinoma in Mice Cancer Prevention Research, September 1, 2008; 1(4): 285 - 297. [Abstract] [Full Text] [PDF]

				C.-X. Xu, D. Jere, H. Jin, S.-H. Chang, Y.-S. Chung, J.-Y. Shin, J.-E. Kim, S.-J. Park, Y.-H. Lee, C.-H. Chae, et al. Poly(ester amine)-mediated, Aerosol-delivered Akt1 Small Interfering RNA Suppresses Lung Tumorigenesis Am. J. Respir. Crit. Care Med., July 1, 2008; 178(1): 60 - 73. [Abstract] [Full Text] [PDF]